UK hypertension study shows 37% prevalence with 59% undetected in 1.4 million adults

Researchers used clinic readings from 2022-2025 enrollees, defining hypertension as systolic ≥140 mmHg, diastolic ≥90 mmHg, or current medication use. Age-standardized prevalence reached 42% in men versus 29% in women, climbing from 15% in 18-39 year olds to 71% at age 80+. Only half of treated patients achieved control below 140/90 mmHg, unchanged from prior decades despite NICE pathways requiring confirmatory readings and initial lifestyle advice. The findings align with observational data from the Health Survey for England and echo Lancet Commission reports on global hypertension gaps, where delayed diagnosis links directly to excess strokes and myocardial infarctions. Oxford authors note that risk-based initiation, rather than repeated thresholds alone, could close the detection loop, especially as cardiovascular risk prediction tools already exist in primary care. England's stagnant control rates contrast with Canada's 68% awareness achieved through systematic screening; without population-level programs, projected CVD events will continue rising. Next steps include piloting single-visit risk-plus-BP protocols in high-deprivation areas to test whether earlier pharmacotherapy reduces events within five years.